Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RET rearrange||lung non-small cell carcinoma||predicted - sensitive||Sunitinib||Clinical Study||Actionable||In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/9, all partial responses), and stable disease in 33% (3/9) of patients following Sutent (sunitinib) treatment (PMID: 28447912).||28447912|
|RET rearrange||lung non-small cell carcinoma||predicted - sensitive||Sunitinib||Clinical Study - Cohort||Actionable||In a Phase II trial, Sutent (sunitinib) treatment resulted in no objective responses (n=7) and a stable disease in 71% (5/7) of non-small cell lung carcinoma patients harboring RET rearrangement (PMID: 32312893; NCT01829217).||32312893|
|PubMed Id||Reference Title||Details|
|(28447912)||Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.||Full reference...|
|(32312893)||Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer.||Full reference...|